LMED 最新10-Q变化
将 LMED 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-11 与上一份 10-Q · 2026-05-20
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +13 | −15 | 0 | 2 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼、风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-11
We had no revenue for the three or six months ended June 30, 2026 and 2025
Operating expenses increased to $77,045 for the three months ended June 30, 2026, from $19,854 for the same period ended June 30, 2025. Operating expenses increased to $120,429 for the six months ended June 30, 2026, from $35,821 for the same period ended June 30, 2025. The increase in operating exp…
We had other expense of $10,363 for the three months ended June 30, 2026, as compared with other expenses of $9,328 for the three months ended June 30, 2025. We had other expense of $19,792 for the six months ended June 30, 2026, as compared with other expenses of $17,816 for the six months ended Ju…
We recorded a net loss of $87,408 for the three months ended June 30, 2026, as compared with a net loss of $29,182 for the three months ended June 30, 2025. We recorded a net loss of $140,221 for the six months ended June 30, 2026, as compared with a net loss of $33,783 for the six months ended June…
Going concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $29,741,007 since its inception and …
相对上期删除的文字 · 来源:10-Q · 2026-05-20
During the quarter ended March 31, 2026, the Company undertook a strategic transition toward the development of artificial intelligence-enabled healthcare technology solutions and related healthcare services infrastructure focused on Latin America.
On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired certain proprietary healthcare technology assets and intellectual property relating to an artificial intelligence-enabled healthcare analytics platform and a technology-enabled healthcare service…
In connection with the Company’s strategic transition, the Company also established and organized operations through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., which is intended to serve as the Company’s operating entity in Venezuela and support its broader Latin American bus…
During April 2026, certain intellectual property assets acquired by the Company were assigned to the subsidiary as part of an internal operational reorganization. Prior to such assignment, the subsidiary had no material operations, assets, liabilities, or standalone financial history.
Current activities are focused on organizational development, operational structuring, technology evaluation, regulatory planning, and business development initiatives related to the Company’s intended healthcare technology platform and services model.
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议